<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33852979</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Season>Jun-Jul</Season></PubDate></JournalIssue><Title>Atencion primaria</Title><ISOAbbreviation>Aten Primaria</ISOAbbreviation></Journal><ArticleTitle>[Basic aspects of COVID-19 for management from primary care].</ArticleTitle><Pagination><StartPage>101966</StartPage><MedlinePgn>101966</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101966</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aprim.2020.12.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0212-6567(20)30356-5</ELocationID><Abstract><AbstractText>SARS-CoV-2 is transmitted from person to person by inhalation or contact with respiratory droplets and aerosols. The median incubation period is 5.1 days. Fever, dry cough, dyspnea and fatigue are the most common symptoms. Almost half of the cases are asymptomatic. The spectrum of disease varies from mild (81%) to critical (5%). Older age, male gender and comorbidities negatively impact on the severity and mortality of COVID-19. The diagnosis of acute COVID-19 is made with RT-PCR or antigenic detection tests. In hospital patients, remdesivir reduces recovery time. Oral steroids are recommended for severe or critical cases requiring oxygen therapy or mechanical ventilation. Thromboprophylaxis is recommended in all severe and non-severe cases with high thrombotic risk. Antibiotherapy is limited to cases of high suspicion of bacterial superinfection. Mild-moderate and severe cases after discharge from hospital should be clinically monitored for a minimum period of two weeks.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molero-Garc&#xed;a</LastName><ForeName>Jos&#xe9; Mar&#xed;a</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>CS San Andr&#xe9;s, DA CENTRO (SERMAS), Grupo de trabajo de enfermedades infecciosas de SemFYC, Madrid, Espa&#xf1;a. Electronic address: jmolerog@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arranz-Izquierdo</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria de Illes Balears (Idisba), CS Escola Graduada, Ibsalut, Palma de Mallorca, Illes Balears, Grupo de trabajo de enfermedades infecciosas de SemFYC, Illes Balears, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez-P&#xe9;rez</LastName><ForeName>Mar&#xed;a Isabel</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>CS Delicias I (GAP Oeste) Valladolid, Coordinadora del Grupo de trabajo de enfermedades infecciosas de SemFYC, Valladolid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redondo S&#xe1;nchez</LastName><ForeName>Jes&#xfa;s Mar&#xed;a</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>CS Ram&#xf3;n y Cajal, DA OESTE (SERMAS), Grupo de trabajo de enfermedades infecciosas de SoMaMFyC, Alcorc&#xf3;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Aspectos b&#xe1;sicos de la COVID-19 para el manejo desde atenci&#xf3;n primaria.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Aten Primaria</MedlineTA><NlmUniqueID>9111075</NlmUniqueID><ISSNLinking>0212-6567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000359" MajorTopicYN="N">Aftercare</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El SARS-CoV-2 se transmite de persona a persona por inhalaci&#xf3;n o por el contacto con gotas y aerosoles respiratorios. El per&#xed;odo de incubaci&#xf3;n mediano es 5,1 d&#xed;as. Fiebre, tos seca, disnea y fatiga, son los s&#xed;ntomas m&#xe1;s comunes. Casi la mitad de los casos son asintom&#xe1;ticos. El espectro de la enfermedad var&#xed;a desde cuadros leves (81%) a cr&#xed;ticos (5%). La edad avanzada, el sexo masculino y las comorbilidades impactan negativamente sobre la gravedad y la mortalidad de la COVID-19. El diagn&#xf3;stico de la patolog&#xed;a aguda se realiza con pruebas de reacci&#xf3;n en cadena de la polimerasa con transcriptasa inversa (RT-PCR) o de detecci&#xf3;n antig&#xe9;nica. En pacientes hospitalizados, el remdesivir reduce el tiempo de recuperaci&#xf3;n. Los corticoides orales se recomiendan en casos graves o cr&#xed;ticos que requieren oxigenoterapia o ventilaci&#xf3;n mec&#xe1;nica. La tromboprofilaxis se sugiere en todos los casos graves y no graves con riesgo tromb&#xf3;tico alto. La antibioterapia se limita a pacientes de alta sospecha de sobreinfecci&#xf3;n bacteriana. Los casos leves-moderados y graves tras el alta hospitalaria deben monitorizarse cl&#xed;nicamente durante un per&#xed;odo m&#xed;nimo de dos semanas</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID prolongado</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 diagnostic testing</Keyword><Keyword MajorTopicYN="N">COVID-19 drug treatment</Keyword><Keyword MajorTopicYN="N">Diagn&#xf3;stico</Keyword><Keyword MajorTopicYN="N">Family practice</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Medicina de familia</Keyword><Keyword MajorTopicYN="N">Tratamiento farmacol&#xf3;gico COVID-19</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33852979</ArticleId><ArticleId IdType="pmc">PMC7762708</ArticleId><ArticleId IdType="doi">10.1016/j.aprim.2020.12.007</ArticleId><ArticleId IdType="pii">S0212-6567(20)30356-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>RENAVE. Informe n&#xb0; 65. Situaci&#xf3;n de COVID-19 en Espa&#xf1;a a 10 de febrero de 2021. [Consultado 15 Feb 2021]; Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFOR...MES/Informes%20COVID-19/INFOR...MES%20COVID-19%202021/Informe%20COVID-19.%20N%C2%BA%2065_10%20de%20febrero%20de%202021.pdf.</Citation></Reference><Reference><Citation>Equipo COVID-19. RENAVE. CNE. CNM (ISCIII) Informe n&#xb0; 33. An&#xe1;lisis de los casos de COVID-19 notificados a la RENAVE hasta el 10 de mayo en Espa&#xf1;a a 29 de mayo de 2020. 2020 https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%c2%ba%2033.%20An%c3%a1lisis%20de%20los%20casos%20de%20COVID-19%20hasta%20el%2010%20de%20mayo%20en%20Espa%c3%b1a%20a%2029%20de%20mayo%20de%202020.pdf.</Citation></Reference><Reference><Citation>Centro de Coordinaci&#xf3;n de Alertas y Emergencias Sanitarias Informaci&#xf3;n cient&#xed;fico-t&#xe9;cnica. Enfermedad por coronavirus, COVID 19. 2020 https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/ITCoronavirus.pdf.</Citation></Reference><Reference><Citation>Kamps B.S., Hoffmann C. Steinh&#xe4;user Verlag; Hamburgo: 2020. COVID Reference. 1-486, https://amedeo.com/CovidReference05.pdf.</Citation></Reference><Reference><Citation>Meyerowitz E.A., Richterman A., Gandhi R.T., Sax P.E. Transmission of SARS-CoV-2: A review of viral host, and environmental factors. Ann Intern Med. 2020;17:M20&#x2013;M5008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505025</ArticleId><ArticleId IdType="pubmed">32941052</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M., Tate M., Lloyd O., Maraolo A.E., Schafers J., Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2020 doi: 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80:656&#x2013;665. doi: 10.1016/j.jinf.2020.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.041</ArticleId><ArticleId IdType="pmc">PMC7151416</ArticleId><ArticleId IdType="pubmed">32283155</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes E.K., Zambrano L.D., Anderson K.N., Marder E., Raz K.M., Felix S.E.B. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. Morb Mortal Wkly Rep. 2020;69:759&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302472</ArticleId><ArticleId IdType="pubmed">32555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683&#x2013;690. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W-T., Toh H.S., Liao C-T., Yu W-L. Cardiac Involvement of COVID-19: A comprehensive review. Am J Med Sci. 2020 doi: 10.1016/j.amjms.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC7536131</ArticleId><ArticleId IdType="pubmed">33187633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Deng C., Chen X., Zhang X., Chen B., Yu H. Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. Acta Ophthalmol. 2020;98:e951&#x2013;e959. https://doi.org/10.1111/aos.14472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276826</ArticleId><ArticleId IdType="pubmed">32421258</ArticleId></ArticleIdList></Reference><Reference><Citation>Galv&#xe1;n-Casas C., Catal&#xe0; A., Carretero-Hern&#xe1;ndez G., Rodr&#xed;guez-Jim&#xe9;nez P., Fern&#xe1;ndez-Nieto D., Rodr&#xed;guez-Villa A. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71&#x2013;77. doi: 10.1111/bjd.19163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19163</ArticleId><ArticleId IdType="pmc">PMC7267236</ArticleId><ArticleId IdType="pubmed">32348545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta N.S., Mytton O.T., Mullins E.W.S., Fowler T.A., Falconer C.L., Murphy O.B. SARS-CoV-2 (COVID-19): What do we know about children? A systematic review. Clin Infect Dis. 2020;71:2469&#x2013;2479. doi: 10.1093/cid/ciaa556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa556</ArticleId><ArticleId IdType="pmc">PMC7239259</ArticleId><ArticleId IdType="pubmed">32392337</ArticleId></ArticleIdList></Reference><Reference><Citation>Noor F.M., Islam M.M. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. J Community Health. 2020;45:1270&#x2013;1282. doi: 10.1007/s10900-020-00920-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10900-020-00920-x</ArticleId><ArticleId IdType="pmc">PMC7486583</ArticleId><ArticleId IdType="pubmed">32918645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano L.D., Ellington S., Strid P., Galang R.R., Oduyebo T., Tong V.T. Update: Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status &#x2014; United States, January 22&#x2013;October 3, 2020. Morb Mortal Wkly Rep. 2020;69:1641&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643892</ArticleId><ArticleId IdType="pubmed">33151921</ArticleId></ArticleIdList></Reference><Reference><Citation>Annweiler C., Sacco G., Salles N., Aquino J.P., Gautier J., Berrut G. National French survey of COVID-19 symptoms in people aged 70 and over. Clin Infect Dis. 2020:ciaa792. doi: 10.1093/cid/ciaa792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa792</ArticleId><ArticleId IdType="pmc">PMC7337693</ArticleId><ArticleId IdType="pubmed">32556328</ArticleId></ArticleIdList></Reference><Reference><Citation>Struyf T., Deeks J.J., Dinnes J., Takwoingi Y., Davenport C., Leeflang M.M. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020;7 doi: 10.1002/14651858.CD013665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013665</ArticleId><ArticleId IdType="pmc">PMC7386785</ArticleId><ArticleId IdType="pubmed">32633856</ArticleId></ArticleIdList></Reference><Reference><Citation>Berenguer J., Ryan P., Rodr&#xed;guez-Ba&#xf1;o J., Jarr&#xed;n I., Carratal&#xe0; J., Pach&#xf3;n J. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26:1525&#x2013;1536. doi: 10.1016/j.cmi.2020.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7399713</ArticleId><ArticleId IdType="pubmed">32758659</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D., Zhou F., Luo L., Xu M., Wang H., Xia J. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7:e671&#x2013;e678. doi: 10.1016/S2352-3026(20)30217-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30217-9</ArticleId><ArticleId IdType="pmc">PMC7351397</ArticleId><ArticleId IdType="pubmed">32659214</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeching NJ. Fletcher TE.Fowler T. BMJ Best Practice. Enfermedad de coronavirus 2019 (COVID-19). https://bestpractice.bmj.com/topics/es-es/3000168/diagnosis-approach</Citation></Reference><Reference><Citation>Datta S.D., Talwar A., Lee J.T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 Infection: illness beyond acute infection and public health implications. JAMA. 2020;324:2251&#x2013;2252. doi: 10.1001/jama.2020.22717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22717</ArticleId><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html</Citation></Reference><Reference><Citation>World Health Organization . WHO; Ginebra: 2020. Diagnostic testing for SARS-CoV-2: interim guidance. https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2.</Citation></Reference><Reference><Citation>Sun J., Xiao J., Sun R., Tang X., Liang C., Lin H. Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg Infect Dis. 2020;26:1834&#x2013;1838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>KCDC Findings from investigation and analysis of re-positive cases. Update2020-05-21. 2020 https://www.cdc.go.kr/board/board.es?mid=a30402000000&amp;bid=0030&amp;act=view&amp;list_no=367267&amp;nPage=2.</Citation></Reference><Reference><Citation>Rao S.N., Manissero D., Steele V.R., Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020;9:573&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386165</ArticleId><ArticleId IdType="pubmed">32725536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio Sanidad Estrategia de detecci&#xf3;n precoz, vigilancia y control de COVID-19. Versi&#xf3;n 12.11.2020. 2020 https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control . ECDC; Stockholm: 2020. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. https://www.ecdc.europa.eu/sites/default/files/documents/Options-use-of-rapid-antigen-tests-for-COVID19-19-11-2020.pdf.</Citation></Reference><Reference><Citation>World Health Organization (WHO) WHO; Geneva: 2020. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infectionusing-rapid-immunoassays.</Citation></Reference><Reference><Citation>Merino P., Guinea J., Mu&#xf1;oz I., Gonz&#xe1;lez P., Gal&#xe1;n J.C., Antona N., Spanish Panbio&#x2122; COVID-19 validation group &#x2021; Multicenter evaluation of the Panbio&#x2122; COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection. medRxiv. 2020 doi: 10.1101/2020.11.18.20230375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.18.20230375</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou B., Li T-D., Zheng S-F., Su Y-Y., Li Z-Y., Liu W. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020;56:2000763. doi: 10.1183/13993003.00763-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00763-2020</ArticleId><ArticleId IdType="pmc">PMC7401320</ArticleId><ArticleId IdType="pubmed">32430429</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Information and Quality Authority (HIQA) Evidence summary of inmunity response following infection with COVID-19. 2020 https://www.hiqa.ie/sites/default/files/2020-05/Evidence-Summary_RQ9-Immunity_0.pdf.</Citation></Reference><Reference><Citation>Deeks J.J., Dinnes J., Takwoingi Y., Davenport C., Spijker R., Taylor-Phillips S. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6:CD013652. doi: 10.1002/14651858.CD013652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013652</ArticleId><ArticleId IdType="pmc">PMC7387103</ArticleId><ArticleId IdType="pubmed">32584464</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Information and Quality Authority (HIQA) Duration of immunity and reinfection following SARS-CoV-2 infection. 2020 https://www.hiqa.ie/sites/default/files/2020-11/Advice_Duration-of-immunity-and-reinfection-following-SARS-CoV-2-infection.pdf.</Citation></Reference><Reference><Citation>Islam N., Salameh J.P., Leeflang M.M., Hooft L., McGrath T.A., Van Der Pol C.B. Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database Syst Rev. 2020;9 doi: 10.1002/14651858.CD013639.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013639.pub3</ArticleId><ArticleId IdType="pubmed">32997361</ArticleId></ArticleIdList></Reference><Reference><Citation>Akl E., Appiah J.A., Blazic I., Fatehi M., Flor N., Frija G. OMS; Ginebra: 2020. Manual de orientaci&#xf3;n r&#xe1;pida para la utilizaci&#xf3;n de estudios radiol&#xf3;gicos de t&#xf3;rax en el diagn&#xf3;stico de la COVID-19; pp. 1&#x2013;56.</Citation></Reference><Reference><Citation>Zarifian A., Nour M.G., Rezayat A.A., Oskooei R.R., Abbasi B., Sadeghi R. Chest CT findings of coronavirus disease 2019 (COVID-19): A comprehensive meta-analysis of 9907 confirmed patients. Clin Imaging. 2020;70:101&#x2013;110. doi: 10.1016/j.clinimag.2020.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinimag.2020.10.035</ArticleId><ArticleId IdType="pmc">PMC7585632</ArticleId><ArticleId IdType="pubmed">33142125</ArticleId></ArticleIdList></Reference><Reference><Citation>OPS/HSS/MT/COVID Aspectos t&#xe9;cnicos y regulatorios sobre el uso de ox&#xed;metros de pulso en el monitoreo de pacientes con COVID-19. 2020 https://iris.paho.org/bitstream/handle/10665.2/52551/OPSHSSMTCOVID-19200029_spa.pdf?sequence=1&amp;isAllowed=y.</Citation></Reference><Reference><Citation>Arribas J.M., Garcia-Vidal C., Pa&#xf1;o J.R., Rodr&#xed;guez J., Paredes R., Estrada V., Siimonetti A.F. SEIMC; Madrid: 2020. Recomendaciones SEIMC para el manejo cl&#xed;nico de pacientes con COVID-19, [Internet]. Actualizado: 9 dic 2020. [Consultado 5 feb 2020]. Disponible en: https://covid19.seimc.org/index.php/recomendaciones-de-tratamiento/</Citation></Reference><Reference><Citation>Sundararaj J.S., Sethuraman N., Gupta R., Thiruvoth S., Gupta M., Ryo A. Treating COVID-19: are we missing out the window of opportunity? J Antimicrob Chemother. 2020:dkaa442. doi: 10.1093/jac/dkaa442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa442</ArticleId><ArticleId IdType="pmc">PMC7665528</ArticleId><ArticleId IdType="pubmed">33099620</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . NICE; London: 2020. COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19. https://www.nice.org.uk/advice/es27/resources/covid-19-rapid-evidence-summary-remdesivir-for-treating-hospitalised-patients-with-suspected-or-confirmed-covid19-pdf-1158180847045.</Citation></Reference><Reference><Citation>Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., WHO Solidarity Trial Consortium Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med. 2020 doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis. JAMA. 2020;324:1330&#x2013;1341. doi: 10.1001/jama.2020.17023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieswerda E., De Boer M.G.J., Bonten M.M.J., Boersma W.G., Jonkers R.E., Aleva R.M. Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline. Clin Microbiol Infect. 2020;27:61&#x2013;66. doi: 10.1016/j.cmi.2020.09.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.041</ArticleId><ArticleId IdType="pmc">PMC7527308</ArticleId><ArticleId IdType="pubmed">33010444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y-F., Pan L-Y., Zhang W-W., Cheng F., Hu S-S., Zhang X. A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis. 2020;100:34&#x2013;41. doi: 10.1016/j.ijid.2020.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.08.023</ArticleId><ArticleId IdType="pmc">PMC7425668</ArticleId><ArticleId IdType="pubmed">32798659</ArticleId></ArticleIdList></Reference><Reference><Citation>Piera-Carbonell A., Fr&#xed;as-Vargas M., Garc&#xed;a-Vallejo O., Garc&#xed;a-Ler&#xed;n A., Cabrera-Ferriols M.A., Peir&#xf3;-Morant J. COVID-19 y tromboprofilaxis: recomendaciones para nuestra pr&#xe1;ctica cl&#xed;nica en Atenci&#xf3;n Primaria. Semergen. 2020;46:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7500906</ArticleId><ArticleId IdType="pubmed">33046353</ArticleId></ArticleIdList></Reference><Reference><Citation>semFYC . semFYC; Barcelona: 2020. Continuidad asistencial al alta en pacientes con diagn&#xf3;stico de neumon&#xed;a por SARS-CoV-2. Conciliaci&#xf3;n de la medicaci&#xf3;n. https://www.semfyc.es/wp-content/uploads/2020/04/Covid19-criterios-24-04-2020.pdf.</Citation></Reference><Reference><Citation>SEDISA  Documento para la atenci&#xf3;n integral al paciente post-COVID. 2020 [consultado 15 Feb 2021]. Disponible en:  https://sedisa.net/wp-content/uploads/2020/10/DocumentoAtencionIntegralPost-Covid.pdf.</Citation></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F., Gemelli Against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Rose E.B., Shapiro N.I., Files D.C. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network &#x2014; United States, March&#x2013;June 2020. Morb Mortal Wkly Rep. 2020;69:993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Zer&#xf3;n P., Conangla L., Kostov B., Moragas A., Ramos M., Sequeira E., Sis&#xf3; A. 1&#xaa; ed. Sociedad Catalana de Medicina Familiar i Comunit&#xe0;ria (CAMFiC); Barcelona: 2020. Manifestaciones persistentes de la COVID-19. Gu&#xed;a de pr&#xe1;ctica cl&#xed;nica [Internet] pp. 1&#x2013;43. [Consulado 15 feb 2020]. Disponible en: https://www.semfyc.es/formacion-y-recursos/manifestaciones-persistentes-de-la-covid-19-guia-de-practica-clinica/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>